E-MEXP-3802 - Transcription profiling by array of HDMVEC, Fibroblast cells, as well as human glioblastoma brain tumor cell line (U87) to investigate the effect of Everolimus (RAD001)

Released on 12 November 2013, last updated on 3 May 2014
Homo sapiens
Samples (18)
Array (1)
Protocols (12)
The effect of Everolimus (RAD001) on primary isolated human dermal microvascular endothelial (HDMVEC) and Fibroblast Cells as well as human glioblastoma brain tumor cell line (U87).
Experiment types
transcription profiling by array, cell type comparison, co-expression, compound treatment, in vivo
mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. Weiler M, Blaes J, Pusch S, Sahm F, Czabanka M, Luger S, Bunse L, Solecki G, Eichwald V, Jugold M, Hodecker S, Osswald M, Meisner C, Hielscher T, Rübmann P, Pfenning PN, Ronellenfitsch M, Kempf T, Schnölzer M, Abdollahi A, Lang F, Bendszus M, von Deimling A, Winkler F, Weller M, Vajkoczy P, Platten M, Wick W. :409-414 (2014), Europe PMC 24367102
Deciphering the systems biology of mTOR inhibition by integrative transcriptome analysis. Domhan S, Schwager C, Wei Q, Muschal S, Sommerer C, Morath C, Wick W, Maercker C, Debus J, Zeier M, Huber PE, Abdollahi A. Current Pharmaceutical Design  (2013)
Investigation descriptionE-MEXP-3802.idf.txt
Sample and data relationshipE-MEXP-3802.sdrf.txt
Raw data (1)E-MEXP-3802.raw.1.zip
Array designA-MEXP-833.adf.txt